4 Biotech Firms Face Hurdles Amid a Shifting COVID-19 Vaccine Landscape
U.S. Vaccine Innovation at Risk: How Four Biotechs Are Being Squeezed by Shifting Policies, Funding Cuts, and Regulatory Changes As the World Health Organization (WHO) sets a new course for…
World Health Assembly Extends Global Digital Health Strategy to 2027, Approves 2028–2033 Phase
World Health Assembly Approves Extension of Global Digital Health Strategy to 2027 and Greenlights Next Phase for 2028–2033 In a landmark decision underscoring the accelerating global commitment to digital health,…
Cullinan, Taiho to Present Positive Zipalertinib Phase 2b Results at ASCO 2025
Cullinan Therapeutics and Taiho Highlight Promising Phase 2b Results of Zipalertinib in Advanced EGFR ex20ins NSCLC at ASCO 2025 Cullinan Therapeutics,in collaboration with Taiho Pharmaceutical Co., Ltd., and its U.S.…
XTANDI Delivers Long-Term Survival in Metastatic Hormone-Sensitive Prostate Cancer
Astellas and Pfizer Showcase Five-Year Survival Benefits of XTANDI in Metastatic Hormone-Sensitive Prostate Cancer at ASCO 2025 In a pivotal milestone for prostate cancer treatment, Astellas Pharma Inc. and Pfizer…
Walgreens Clinical Trials: 3 Strategies for Patient-Centered Engagement
Bringing Research to the People: How Walgreens Clinical Trials is Revolutionizing Patient Engagement Over the past three years, Walgreens has made remarkable strides in democratizing access to clinical trials. Through…
Court Blocks HHS Layoff and Restructuring Plans, Citing Overreach of Authority
Federal Judge Blocks Trump Administration’s Sweeping HHS Layoff and Reorganization Plan, Citing Lack of Legal Authority A federal judge in California has issued a significant legal blow to the Trump…
EU Recommends Approval of Eylea™ 8 mg with Extended 6-Month Dosing Interval
Bayer’s Eylea™ 8 mg Recommended for EU Approval with Extended 6-Month Treatment Interval for Major Retinal Diseases Bayer has today announced a significant milestone in the treatment of retinal diseases,…
CHMP Backs Blenrep Combos for Relapsed/Refractory Multiple Myeloma
GSK’s Blenrep Combinations Receive Positive CHMP Opinion for Relapsed or Refractory Multiple Myeloma, Signaling Expanded Access Across Europe In a significant step forward for the treatment of multiple myeloma, GSK…
NICE in England Recommends FILSPARI for the Treatment of IgA Nephropathy
NICE Recommends FILSPARI® (sparsentan) for Routine Use in the NHS to Treat Adults with IgA Nephropathy, Marking a Significant Step Forward in Rare Kidney Disease Management CSL Vifor has announced…
CVS Health Survey Reveals Smoking Trends Among Young Adults
Rethinking Nicotine: CVS Health Survey Uncovers Widespread Misconceptions About E-Cigarette Safety Among Young Adults Over the past few decades, the public conversation around tobacco and nicotine use has transformed dramatically.…
ASCENT-03: Trodelvy Significantly Improves PFS in First-Line mTNBC Patients Ineligible for Checkpoint Inhibitors
Trodelvy Marks Breakthrough in First-Line mTNBC Treatment with Positive Phase 3 ASCENT-03 Results Gilead Sciences has announced encouraging topline results from its Phase 3 ASCENT-03 clinical trial evaluating Trodelvy® (sacituzumab…
Bayer Launches Centafore Imaging Core Lab for Clinical Trials and SaMD Development
Bayer Launches Centafore Imaging Core Lab to Revolutionize Clinical Trial Imaging and SaMD Development Bayer, a global leader in healthcare and life sciences, today officially announced the launch of its…